• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Convalescent plasma - this is no time for competition.

作者信息

Farrugia Albert, MacPherson Jim, Busch Michael P

机构信息

School of Surgery, Faculty of Medicine and Surgery, The University of Western Australia, Perth, Australia.

MacPherson Strategies, Global Healing, Ann Arbor, MI, USA.

出版信息

Transfusion. 2020 Jul;60(7):1644-1646. doi: 10.1111/trf.15922. Epub 2020 Jun 25.

DOI:10.1111/trf.15922
PMID:32533558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7323360/
Abstract
摘要

相似文献

1
Convalescent plasma - this is no time for competition.康复血浆——现在不是竞争的时候。
Transfusion. 2020 Jul;60(7):1644-1646. doi: 10.1111/trf.15922. Epub 2020 Jun 25.
2
Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials.新冠康复者血浆的安全性：一项关于随机对照试验的确定性系统评价和荟萃分析。
Transfusion. 2024 Feb;64(2):388-399. doi: 10.1111/trf.17701. Epub 2023 Dec 29.
3
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma.探讨 COVID19 恢复期血浆疗效试验的可能性艺术。
Int J Infect Dis. 2021 Jan;102:244-246. doi: 10.1016/j.ijid.2020.10.074. Epub 2020 Oct 30.
4
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
5
[Is convalescent plasma an alternative treatment for Covid-19 patients?].[康复期血浆是新冠病毒肺炎患者的替代治疗方法吗？]
Salud Publica Mex. 2020 Nov-Dec;62(6):870-871. doi: 10.21149/11744.
6
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
7
COVID-19 convalescent plasma: Interim recommendations from the AABB.新型冠状病毒肺炎康复者血浆：美国血库协会临时建议
Transfusion. 2021 Apr;61(4):1313-1323. doi: 10.1111/trf.16328. Epub 2021 Mar 7.
8
Covid-19 convalescent plasma and SARS-CoV-2 viral variants.新冠康复者血浆与严重急性呼吸综合征冠状病毒2病毒变体
Transfus Clin Biol. 2021 Aug;28(3):306. doi: 10.1016/j.tracli.2021.05.008. Epub 2021 May 29.
9
Convalescent plasma for COVID-19 - encouraging signals of efficacy.用于治疗新冠肺炎的康复期血浆——疗效的鼓舞人心信号。
Br J Haematol. 2021 Feb;192(4):681-682. doi: 10.1111/bjh.17270. Epub 2021 Feb 1.
10
Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.需要进行对照试验以证明恢复期血浆疗法对2019冠状病毒病的疗效和安全性。
Ann Allergy Asthma Immunol. 2021 Feb;126(2):122-123. doi: 10.1016/j.anai.2020.11.005. Epub 2020 Nov 5.

引用本文的文献

1
Hyperimmune immunoglobulin for people with COVID-19.COVID-19 免疫球蛋白
Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD015167. doi: 10.1002/14651858.CD015167.pub2.
2
A Transient Effect of Convalescent Plasma Therapy in a Patient with Severe Covonavirus Disease 2019: A Case Report.康复期血浆疗法对一名重症2019冠状病毒病患者的短暂疗效：一例报告
Infect Chemother. 2022 Sep;54(3):553-558. doi: 10.3947/ic.2020.0089. Epub 2022 Jun 22.
3
Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.CoviFab，一种源自马多克隆抗体的 RBD 特异性 F(ab')2 片段，其非临床安全性评估和体内生物分布。
Toxicol Appl Pharmacol. 2022 Jan 1;434:115796. doi: 10.1016/j.taap.2021.115796. Epub 2021 Nov 14.
4
COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.COVID-19 与高免疫血清：对抗冠状病毒的可行方案 B。
Int Immunopharmacol. 2021 Jan;90:107220. doi: 10.1016/j.intimp.2020.107220. Epub 2020 Nov 20.

本文引用的文献

1
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.46 例重症 COVID-19 患者接受免疫血浆治疗后的死亡率降低：一项概念验证性单臂多中心试验。
Haematologica. 2020 Dec 1;105(12):2834-2840. doi: 10.3324/haematol.2020.261784.
2
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.恢复期血浆治疗重症 COVID-19：一项倾向评分匹配对照研究。
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
3
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.新冠病毒肺炎患者中中和抗体反应的快速产生
Cell Rep Med. 2020 Jun 23;1(3):100040. doi: 10.1016/j.xcrm.2020.100040. Epub 2020 Jun 8.
4
Early safety indicators of COVID-19 convalescent plasma in 5000 patients.5000 例 COVID-19 恢复期血浆治疗的早期安全性指标。
J Clin Invest. 2020 Sep 1;130(9):4791-4797. doi: 10.1172/JCI140200.
5
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
6
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.恢复期血浆疗法治疗重症 COVID-19 患者的疗效。
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.
7
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.恢复期血浆治疗严重急性呼吸综合征冠状病毒 2 感染的危重症患者。
Chest. 2020 Jul;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039. Epub 2020 Mar 31.
8
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
9
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.免疫球蛋白治疗住院的呼吸道合胞病毒感染婴幼儿
Cochrane Database Syst Rev. 2019 Aug 26;8(8):CD009417. doi: 10.1002/14651858.CD009417.pub2.
10
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review.帕利珠单抗预防呼吸道合胞病毒感染的成本效果评价：系统评价。
Pediatrics. 2019 May;143(5). doi: 10.1542/peds.2018-4064.